BIOMAT Database Logo BIOMAT Database Logo

Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. 2007

G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Department of Oncology, Avicenne Hospital, 93009 Bobigny, France. Gaetan.des-guetz@wanadoo.fr

BACKGROUND Microsatelite instability (MSI) is the consequence of the inactivation of a mismatch repair gene and is observed in approximately 15% of colon cancer cases. Patients with MSI colon cancer do not benefit from 5-fluorouracil (5-FU)-based chemotherapy. A current treatment of reference for colon cancer is a combination of 5-FU and oxaliplatin (FOLFOX). The aim of this study was to determine the efficiency of the FOLFOX treatment in patients with metastatic MSI colon cancer. METHODS Tumour specimens were collected from patients with metastatic colon cancer treated with FOLFOX 4 modified or FOLFOX 6; these two regimens are based on 85 mg/m2 and 100 mg/m2 oxaliplatin, respectively. The MSI status was assessed by measuring the length of five monomorphic mononucleotide markers. The FOLFOX regimen was evaluated as a first-line treatment according to WHO criteria. RESULTS Forty patients (22 men, 18 women), median age 63.5 years (27-83 years) were treated with FOLFOX 4 or 6. Nine patients had tumours exhibiting high MSI (MSI group) and 31 patients had tumours exhibiting microsatellite stability (MSS group). In the MSS group, 11 partial responses (36%) were observed, while there were only two in the MSI group (22%) (no significant difference). The two patients who were responders in the MSI group were treated with FOLFOX 6. The overall survival was not significantly different for MSI and MSS patients. CONCLUSIONS No significant differences in the overall response rate or overall survival between the two groups of patients were observed. However, these results suggest that patients with MSI colon cancer are more sensitive to a higher dose of FOLFOX.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077150 Oxaliplatin An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter- and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS. Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1),1,2-Diaminocyclohexane Platinum Oxalate,1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II),ACT 078,ACT-078,Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II),Eloxatin,Eloxatine,L-OHP Cpd,Oxalato-(1,2-cyclohexanediamine)platinum II,Oxaliplatin, (SP-4-2-(1R-trans))-isomer,Oxaliplatin, (SP-4-2-(1S-trans))-isomer,Oxaliplatin, (SP-4-3-(cis))-isomer,Oxaliplatine,Platinum(II)-1,2-cyclohexanediamine Oxalate,1,2 Diaminocyclohexane Platinum Oxalate,ACT078
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
August 2018, Future oncology (London, England),
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective.
January 2022, Frontiers in oncology,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
January 2009, Targeted oncology,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Mitochondrial microsatellite instability in patients with metastatic colorectal cancer.
May 2015, Virchows Archiv : an international journal of pathology,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite instability in primary and metastatic colorectal cancers.
June 1995, International journal of cancer,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
[Colorectal cancer and microsatellite instability].
April 2005, Medicina clinica,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite instability and colorectal cancer.
October 2011, Archives of pathology & laboratory medicine,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite instability in colorectal cancer.
April 2006, The British journal of surgery,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite instability in colorectal cancer.
January 2018, EXCLI journal,
G des Guetz, and P Mariani, and J Cucherousset, and M Benamoun, and C Lagorce, and X Sastre, and P Le Toumelin, and B Uzzan, and G Y Perret, and J F Morere, and J L Breau, and R Fagard, and P O Schischmanoff
Microsatellite instability in colorectal cancer.
October 2013, Clinical advances in hematology & oncology : H&O,
Copied contents to your clipboard!